Results of a late-stage drug trial conducted by Novo Nordisk show that weight loss drug Wegovy can reduce the risk of heart disease in certain patients. Wegovy was approved by the FDA in 2021 for chronic weight management in adults with obesity or overweight and weight-related conditions.
The Food and Drug Administration first approved Wegovy in 2021 for chronic weight management in adults who are obese or overweight and have at least one weight-related condition, such as high blood pressure, Type 2 diabetes or high cholesterol.
According to the World Health Organization , cardiovascular diseases are the leading cause of death globally with an estimated 17.9 million people dying from such diseases in 2019. Of those deaths, 85% were due toVarious packages of the weight loss drug"Wegovy" from the pharmaceutical company Novo Nordisk on a sales counter in a Danish pharmacy.
Novo also manufactures Ozempic, which is the same medication as Wegovy but has different dosages and FDA-approved intended uses.Ozempic was approved by federal health officials in 2017 and
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Novo's weight-loss drug Wegovy cuts risk of heart disease by 20% - trial dataNovo Nordisk's obesity drug Wegovy has shown a clear medical benefit, reducing the risk of heart disease by 20% according to a large late-stage study. The positive results have boosted the Danish drugmaker's hopes of repositioning Wegovy as more than just a lifestyle drug.
Read more »
Weight-Loss Drug Wegovy Cuts Heart Attack, Stroke Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Read more »
Weight-Loss Drug Wegovy Cuts Stroke, Heart-Attack Risk by 20% in New StudyAnti-obesity drug Wegovy not only helped people lose weight but also reduced their risk of suffering heart attacks, strokes and cardiovascular deaths by 20% in a study
Read more »
Wegovy drug reduces cardiovascular risks by 20%, says drugmakerA new study by drugmaker Novo Nordisk reveals that the weight-loss drug Wegovy has significantly reduced the risk of heart attack, stroke, and cardiovascular death in overweight adults with cardiovascular disease.
Read more »
Novo weight-loss drug Wegovy shows heart benefit in trialNovo Nordisk announced that a trial has revealed that patients taking the weight-loss drug Wegovy had a 20% lower risk of heart attack, stroke, or death from heart disease compared to those on a placebo. This finding gives hope to Novo Nordisk in expanding the perception of Wegovy beyond being just a lifestyle drug.
Read more »
Weight-Loss Drug Wegovy Lowers Major Heart Disease Risk By 20% According To Trial Data—Novo Nordisk Shares SurgeNovo Nordisk's shares rose by more than 16% on Tuesday, as the results of the trial exceeded investor expectations. The weight-loss drug Wegovy lowers the risk of 'adverse cardiovascular events' by 20%, according to data from a major trial shared by the drug's maker Novo Nordisk Tuesday, causing the company's shares to surge.
Read more »